Trial · NCT04773587
Outcomes11
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Achievement of Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Success at Week 4 | Week 4 | All randomized participants are included. | percentage of participants | NUMBER |
| SECONDARY | Achievement of vIGA-AD Success at Week 4 in Participants With Moderate Baseline Scores | Week 4 | All randomized participants who were included in the moderate baseline vIGA-AD group during randomization are included. | percentage of participants | NUMBER |
| SECONDARY | Achievement of a 4-Point Reduction in the Average, Weekly Worst Itch Numeric Rating Scale (WI-NRS) at Week 4 in Participants ≥12 Years of Age With Baseline WI-NRS ≥ 4 | Week 4 | All randomized participants ≥12 years of age with a baseline WI-NRS ≥4 are included. | percentage of participants | NUMBER |
| SECONDARY | Achievement of a 4-Point Reduction in the Average, Weekly WI-NRS at Week 2 in Participants ≥12 Years of Age With Baseline WI-NRS ≥ 4 | Week 2 | All randomized participants ≥12 years of age with a baseline WI-NRS ≥4 are included. | percentage of participants | NUMBER |
| SECONDARY | Achievement of a 4-Point Reduction in the Average, Weekly WI-NRS at Week 1 in Participants ≥12 Years of Age With Baseline WI-NRS ≥ 4 | Week 1 | All randomized participants ≥12 years of age with a baseline WI-NRS ≥4 are included. | percentage of participants | NUMBER |
| SECONDARY | Achievement of ≥ 75% Reduction in the Eczema Area and Severity Index (EASI-75) at Week 4 | Week 4 | All randomized participants are included. | percentage of participants | NUMBER |
| SECONDARY | Achievement of vIGA-AD Score of 'Clear' or 'Almost Clear' at Week 4 | Week 4 | All randomized participants are included. | percentage of participants | NUMBER |
| SECONDARY | Achievement of vIGA-AD Success at Week 2 | Week 2 | All randomized participants are included. | percentage of participants | NUMBER |
| SECONDARY | Achievement of vIGA-AD Success at Week 1 | Week 1 | All randomized participants are included. | percentage of participants | NUMBER |
| SECONDARY | Achievement of vIGA-AD Score of 'Clear' or 'Almost Clear' at Week 2 | Week 2 | All randomized participants are included. | percentage of participants | NUMBER |
| SECONDARY | Achievement of vIGA-AD Score of 'Clear' or 'Almost Clear' at Week 1 | Week 1 | All randomized participants are included. | percentage of participants | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04773587/outcomes